ESC 365 - Aspirin for the Primary Prevention of Cardiovascular Disease – Represented in NEJM by the ASPREE and ASCEND trials (and in Lancet by the ARRIVE trial).

ESC Premium Access

Aspirin for the Primary Prevention of Cardiovascular Disease – Represented in NEJM by the ASPREE and ASCEND trials (and in Lancet by the ARRIVE trial).

Session: Highlights from the New England Journal of Medicine: editors’ choice

Topic: European Society of Cardiology

Speaker: Professor J. Mcneil (Melbourne, AU)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor John Mcneil

Monash University, Melbourne (Australia)

2 presentations

0 follower

2 more presentations in this session

Novel Therapeutic Agents for Transthyretin Amyloidosis – Represented in NEJM by the ATTR-ACT, APOLLO, and NEURO-TTR trials.

Speaker: Professor C. Rapezzi (Ferrara, IT)

Transcatheter Aortic Valve Replacement in Low-Risk Patients – Represented in NEJM by the PARTNER 3 and Evolut Low Risk trials.

Speaker: Doctor M. Mack (Dallas, US)

Access the full session

Highlights from the New England Journal of Medicine: editors’ choice

Speakers: Professor J. Mcneil, Professor C. Rapezzi, Doctor M. Mack

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources